Eric Smith, MD, PhD, discusses the use of armored chimeric antigen receptor T cells in multiple myeloma.
Eric Smith, MD, PhD, a medical oncologist at Memorial Sloan Kettering Cancer Center, discusses the use of armored chimeric antigen receptor (CAR) T cells in multiple myeloma.
At Memorial Sloan Kettering, armored CAR T cells are used to encode at least 2 genes, 1 being the CAR itself and the second being a gene that gives T cells an advantage. According to Smith, it could be a proinflammatory cytokine that make T cells better killers. It could also be a ligand that is expressed on the surface and interacts with other cells in the tumor microenvironment.
Cretostimogene Grenadenorepvec Shows High CR Rate in BCG-Unresponsive NMIBC
July 17th 2024Mark D. Tyson, II, MD, MPH, discussed treatment with cretostimogene grenadenorepvec in high-risk Bacillus Calmette-Guérin-unresponsive non-muscle invasive bladder cancer with carcinoma in situ and data from the BOND-003 trial.
Read More